Skip to main navigation Skip to search Skip to main content

RhoGDI2 suppresses bladder cancer metastasis via reduction of infammation in the tumor microenvironment

Research output: Contribution to journalArticlepeer-review

Abstract

Low expression of RhoGDI2 is associated with poor outcome in cancer patients. In animal models, RhoGDI2 suppresses lung metastasis by reducing the expression of the proteoglycan versican, whose levels portend poor patient prognosis. Versican promotes metastasis through enhanced tumor migration and creation of an inflammatory lung environment involving macrophages and the CCL2/CCR2 signaling axis. Targeting this mechanism may provide novel adjuvant strategies for delaying the appearance of clinical metastasis.
Original languageEnglish
Pages (from-to)1175-1177
Number of pages3
JournalOncoImmunology
Volume1
Issue number7
DOIs
StatePublished - 2012
Externally publishedYes

ASJC Scopus Subject Areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Keywords

  • Bladder cancer
  • Inflammation
  • Metastasis
  • RhoGDI2
  • Versican

Cite this